Moss, 7 January 2026

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of
high-quality diagnostic assays, announces that it has entered into an exclusive
cooperation agreement with a leading global diagnostics company for the
development of a novel assay to be integrated on one of the most widely used
clinical chemistry analyser platforms in the world.

Under the agreement, Gentian is responsible for assay development and will also
undertake manufacturing upon commercialisation.

In line with the partner's strategic communications policy, the identity of the
biomarker and its specific diagnostic application remain undisclosed. The
project is well advanced in the development phase, with current activities
focused on optimisation of assay performance and system integration, as well as
preparations for subsequent validation activities. Subject to successful
completion of development, and regulatory processes, a commercial launch is
currently targeted for the second half of 2027.

Upon launch, the assay will be distributed through the partner's global sales
and distribution network, providing Gentian with broad international market
access and reinforcing its commitment to scalable, high-quality diagnostic
solutions.

This project builds on Gentian's growing portfolio of successfully
commercialized biomarker assays and further solidifies its reputation as a
trusted development and manufacturing partner for global diagnostic leaders.

"We are pleased to see this project advancing into the later stages of
development in close collaboration with a global diagnostics leader," says Matti
Heinonen, CEO of Gentian Diagnostics. "The agreement reflects confidence in our
assay development capabilities and supports our strategy of creating long-term
value through strategic partnerships in the global diagnostics market."

For further information, please contact: 
Njaal Kind, CFO
njaal.kind@gentian.no 
+47 919 06 525

About Gentian Diagnostics 
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.